Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients

被引:86
|
作者
Verburg, FA
de Keizer, B
Lips, CJM
Zelissen, PMJ
de Klerk, JMH
机构
[1] Univ Utrecht, Ctr Med, Dept Nucl Med, NL-3584 CX Utrecht, Netherlands
[2] Univ Utrecht, Ctr Med, Dept Endocrinol, NL-3584 CX Utrecht, Netherlands
关键词
D O I
10.1530/eje.1.01819
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Currently, little is known about the prognostic significance of achieving successful ablation with the first dosage of 1-131 in patients with differentiated thyroid cancer. This study aimed to assess the following: (i) whether successful or unsuccessful ablation at post-ablation follow-up has prognostic consequences; (ii) possible factors predicting success of ablation in a patient. Methods: In order to do this, we retrospectively studied 180 patients with a median follow-up of 55 months. Ablation was considered to be successful if I year after the initial dosage of 1-131 patients fulfilled all of the following criteria: not dead from thyroid cancer, no additional therapy needed for any kind for thyroid cancer within the first year, undetectable thyroglobulin (Tg) levels under TSH stimulation, and negative 1-131. scintigraphy. Tg levels at the time of ablation (P < 0.00.1.), lymph node metastasis (P = 0.04) and distant metastasis (P < 0.001.) have a significant influence on the success of ablation. P values were calculated by Mann-Whitney U test and Chi-square test, respectively. Results: Patients with successful ablation had a better prognosis than those with unsuccessful ablation: disease-free survival was 87%, versus 49% after 10 years; additionally, thyroid-cancer related survival was 93% versus 78%. Conclusion: We conclude that the extent of the remaining normal or neoplastic thyroid tissue influences the outcome of ablation, and that successful ablation leads to a better prognosis. It seems that it is very important to achieve complete ablation as soon as possible in order to ensure the best possible prognosis for a patient.
引用
收藏
页码:33 / 37
页数:5
相关论文
共 50 条
  • [21] Controversies in the Radioiodine Treatment of Patients With Differentiated Thyroid Cancer
    Buscombe, John
    SEMINARS IN NUCLEAR MEDICINE, 2023, 53 (04) : 475 - 480
  • [22] The calculation of the ablation activities for radioiodine therapy of differentiated thyroid cancer with provision for thyroid stunning
    Dzhuzha, DA
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S467 - S467
  • [23] Assessment of radioiodine clearance in patients with differentiated thyroid cancer
    Tabei, F.
    Asli, I. Neshandar
    Azizmohammadi, Z.
    Javadi, H.
    Assadi, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S343 - S343
  • [24] Postoperative radioiodine ablation in patients with low risk differentiated thyroid carcinoma
    Diez, Juan J.
    Grande, Enrique
    Iglesias, Pedro
    MEDICINA CLINICA, 2015, 144 (01): : 35 - 41
  • [25] Assessment of radioiodine clearance in patients with differentiated thyroid cancer
    Tabei, Faraj
    Asli, Isa Neshandar
    Azizmohammadi, Zahra
    Javadi, Hamid
    Assadi, Majid
    RADIATION PROTECTION DOSIMETRY, 2012, 152 (04) : 323 - 327
  • [26] Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?
    Piccardo, Arnoldo
    Puntoni, Matteo
    Ferrarazzo, Giulia
    Foppiani, Luca
    Bottoni, Gianluca
    Altrinetti, Vania
    Treglia, Giorgio
    Naseri, Mehrdad
    Dib, Bassam
    Cabria, Manlio
    Trimboli, Pierpaolo
    Massollo, Michela
    Giovanella, Luca
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (07) : 1218 - 1223
  • [27] Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer
    Tresoldi, Alberto S.
    Sburlati, Laura F.
    Rodari, Marcello
    Schinkelshoek, Mink
    Perrino, Michela
    De Leo, Simone
    Montefusco, Laura
    Colombo, Paolo
    Arosio, Maura
    Lania, Andrea Gerardo Antonio
    Fugazzola, Laura
    Chiti, Arturo
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2014, 37 (08): : 709 - 714
  • [28] Low-Dose Radioiodine Ablation in Patients with Low-Risk Differentiated Thyroid Cancer
    Jimenez Londono, German A.
    Garcia Vicente, Ana Maria
    Sastre Marcos, Julia
    Pena Pardo, Francisco Jose
    Amo-Salas, Mariano
    Moreno Caballero, Manuel
    Talavera Rubio, Maria Prado
    Gonzalez Garcia, Beatriz
    Disotuar Ruiz, Niletys Dafne
    Soriano Castrejon, Angel Maria
    EUROPEAN THYROID JOURNAL, 2018, 7 (04) : 218 - 224
  • [29] Radioiodine Ablation of Remaining Thyroid Lobe in Patients with Differentiated Thyroid Cancer Treated by Lobectomy: A Systematic Review and Metaanalysis
    Piccardo, Arnoldo
    Trimboli, Pierpaolo
    Bottoni, Gianluca
    Giovanella, Luca
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (12) : 1730 - 1735
  • [30] Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?
    Arnoldo Piccardo
    Matteo Puntoni
    Giulia Ferrarazzo
    Luca Foppiani
    Gianluca Bottoni
    Vania Altrinetti
    Giorgio Treglia
    Mehrdad Naseri
    Bassam Dib
    Manlio Cabria
    Pierpaolo Trimboli
    Michela Massollo
    Luca Giovanella
    European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 1218 - 1223